MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$6,382,000
EPS
-$0.1
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
0
0
0
0
Research and development
3,638,000
3,073,000
2,002,000
1,681,000
General and administrative
2,438,000
2,157,000
1,957,000
3,811,000
Impairment loss on intangible assets
-
-
28,700,000
-
Total operating expenses
6,076,000
5,230,000
32,659,000
5,492,000
Loss from operations
-6,076,000
-5,230,000
-32,659,000
-5,492,000
Other (expense) income, net
-299,000
-608,000
-20,000
-89,000
Income tax benefit
-
-
-712,000
-
Net loss
-6,375,000
-5,838,000
-31,967,000
-5,581,000
Unrealized (gain) loss on investments, net of tax of 0
-12,000
0
18,000
0
Foreign currency translation adjustments
5,000
0
-36,000
0
Total other comprehensive loss
-7,000
0
-18,000
0
Total comprehensive loss
-6,382,000
-5,838,000
-31,985,000
-5,581,000
Basic EPS
-0.1
-0.19
-1.091
-0.21
Diluted EPS
-0.1
-0.19
-1.091
-0.21
Basic Average Shares
67,084,661
30,354,647
29,314,367
26,361,386
Diluted Average Shares
67,084,661
30,354,647
29,314,367
26,361,386
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Total comprehensive
loss
-$6,382,000
(6.61%↑ Y/Y)
Net loss
-$6,375,000
(6.55%↑ Y/Y)
Total other
comprehensive loss
-$7,000
(41.67%↑ Y/Y)
Foreign currency
translation adjustments
$5,000
(120.83%↑ Y/Y)
Loss from operations
-$6,076,000
(11.57%↑ Y/Y)
Other (expense)
income, net
-$299,000
(-710.20%↓ Y/Y)
Unrealized (gain) loss on
investments, net of tax of 0
-$12,000
(-200.00%↓ Y/Y)
Total operating
expenses
$6,076,000
(-11.57%↓ Y/Y)
Research and development
$3,638,000
(-15.24%↓ Y/Y)
General and
administrative
$2,438,000
(-5.47%↓ Y/Y)
Buy us a coffee
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)